RESUMO
Labetalol hydrochloride (LHCl), an α- and ß-adrenoreceptor blocker, is widely used for the treatment of hypertension as well as angina pectoris. Previous reports have demonstrated the adverse events during clinical application of LHCl, such as liver injury and acute renal failure. The present study aimed to investigate metabolic activation of LHCl to initiate the elucidation of the mechanisms of its liver toxicity. One glutathione (GSH) conjugate was detected in rat and human primary hepatocytes as well as bile of rats after exposure to LHCl. The GSH conjugate was chemically synthesized and characterized by Q-TOF and 1H NMR. Pretreatment of 2,6-dichloro-4-nitrophenol (DCNP), a broad-spectrum sulfotransferase (SULT) inhibitor, significantly attenuated the formation of the GSH conjugate in LHCl-treated hepatocytes and animals, indicating the participation of SULTs in metabolic activation of LHCl. Moreover, pretreatment with DCNP displayed significant protection against the observed cytotoxicity in rat primary hepatocytes, which suggests a correlation of the bioactivation of LHCl mediated by SULTs with LHCl-induced hepatotoxicity.
Assuntos
Hepatócitos/efeitos dos fármacos , Labetalol/farmacologia , Sulfotransferases/metabolismo , Animais , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Labetalol/química , Labetalol/metabolismo , Masculino , Estrutura Molecular , Ratos , Ratos Sprague-DawleyRESUMO
RATIONAL & OBJECTIVE: Beta-blockers are recommended for patients with heart failure (HF) but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous, including with respect to their removal by hemodialysis. We sought to evaluate whether ß-blocker use and their dialyzability characteristics were associated with early mortality among patients with chronic kidney disease with HF who transitioned to dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults patients with chronic kidney disease (aged≥18 years) and HF who initiated either hemodialysis or peritoneal dialysis during January 1, 2007, to June 30, 2016, within an integrated health system were included. EXPOSURES: Patients were considered treated with ß-blockers if they had a quantity of drug dispensed covering the dialysis transition date. OUTCOMES: All-cause mortality within 6 months and 1 year or hospitalization within 6 months after transition to maintenance dialysis. ANALYTICAL APPROACH: Inverse probability of treatment weights using propensity scores was used to balance covariates between treatment groups. Cox proportional hazard analysis and logistic regression were used to investigate the association between ß-blocker use and study outcomes. RESULTS: 3,503 patients were included in the study. There were 2,115 (60.4%) patients using ß-blockers at transition. Compared with nonusers, the HR for all-cause mortality within 6 months was 0.79 (95% CI, 0.65-0.94) among users of any ß-blocker and 0.68 (95% CI, 0.53-0.88) among users of metoprolol at transition. There were no observed differences in all-cause or cardiovascular-related hospitalization. LIMITATIONS: The observational nature of our study could not fully account for residual confounding. CONCLUSIONS: Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis.
Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Hospitalização/estatística & dados numéricos , Falência Renal Crônica/terapia , Mortalidade , Diálise Renal , Antagonistas Adrenérgicos beta/metabolismo , Idoso , Idoso de 80 Anos ou mais , Atenolol/metabolismo , Atenolol/uso terapêutico , Bisoprolol/metabolismo , Bisoprolol/uso terapêutico , Carvedilol/metabolismo , Carvedilol/uso terapêutico , Causas de Morte , Estudos de Coortes , Feminino , Insuficiência Cardíaca/complicações , Humanos , Falência Renal Crônica/complicações , Labetalol/metabolismo , Labetalol/uso terapêutico , Modelos Logísticos , Masculino , Metoprolol/metabolismo , Metoprolol/uso terapêutico , Pessoa de Meia-Idade , Nadolol/metabolismo , Nadolol/uso terapêutico , Modelos de Riscos Proporcionais , Propranolol/metabolismo , Propranolol/uso terapêutico , Fatores de Proteção , Estudos Retrospectivos , Risco , Fatores de RiscoRESUMO
Metabolically induced drug-toxicity is a major cause of drug failure late in drug optimization phases. Accordingly, in vitro metabolic profiling of compounds is being introduced at earlier stages of the drug discovery pipeline. An increasingly common method to obtain these profiles is through overexpression of key CYP450 metabolic enzymes in immortalized liver cells, to generate competent hepatocyte surrogates. Enhanced cytotoxicity is presumed to be due to toxic metabolite production via the overexpressed enzyme. However, metabolically induced toxicity is a complex multi-parameter phenomenon and the potential background contribution to metabolism arising from the use of liver cells which endogenously express CYP450 isoforms is consistently overlooked. In this study, we sought to reduce the potential background interference by applying this methodology in kidney-derived HEK293 cells which lack endogenous CYP450 expression. Overexpression of CYP3A4 resulted in increased HEK293 proliferation, while exposure to four compounds with reported metabolically induced cytotoxicity in liver-derived cells overexpressing CYP3A4 resulted in no increase in cytotoxicity. Our results indicate that overexpression of a single CYP450 isoform in hepatic cell lines may not be a reliable method to discriminate which enzymes are responsible for metabolic induced cytotoxicity.
Assuntos
Clorpromazina/toxicidade , Citocromo P-450 CYP3A/metabolismo , Células Epiteliais/efeitos dos fármacos , Labetalol/toxicidade , Propranolol/toxicidade , Rosiglitazona/toxicidade , Ativação Metabólica , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Clorpromazina/metabolismo , Citocromo P-450 CYP3A/genética , Células Epiteliais/enzimologia , Células Epiteliais/patologia , Células HEK293 , Humanos , Labetalol/metabolismo , Propranolol/metabolismo , Medição de Risco , Rosiglitazona/metabolismo , Especificidade por Substrato , Testes de ToxicidadeRESUMO
Immobilization of enzymes on carriers have been pursued to make the enzyme stable, reusable and obtaining even better enzyme activity. Due to the highly stable two-dimensional layer structure, large surface area and pore volume, graphene materials were seemed as ideal carrier for enzyme immobilization. In this paper, pristine few layer graphene (FLG) was applied to interact with laccase to synthesize laccase-graphene composite and the results of AFM, FT-IR and adsorption isotherm suggested that laccase was loaded on the FLG with a very high loading dosage (221.1â¯mgâ¯g-1). Based on the measured interaction force and binding type between laccase and graphene, we proposed that the great enzyme loading on FLG is likely due to the non-covalent π-π stacking in addition to the large surface area of FLG. The composite has better stability to the variance of pH and storage temperature than free laccase. The synthesized composite can effectively transform beta-blocker labetalol with an enhanced efficiency, though the possible reaction pathways kept not changing. We further performed molecular simulation study on the crystal structure variation of laccase binding on FLG and proposed that catalytic activity enhancement may be attributed to the more exposure extent of the catalytic center of laccase. In addition, the laccase-graphene composite can be reused more than ten times in catalyzing the labetalol removal.
Assuntos
Antagonistas Adrenérgicos beta/metabolismo , Enzimas Imobilizadas/metabolismo , Grafite/química , Labetalol/metabolismo , Lacase/metabolismo , Adsorção , Catálise , Concentração de Íons de Hidrogênio , Espectroscopia de Infravermelho com Transformada de FourierRESUMO
Why are a few drugs with properties beyond the rule of 5 (bRo5) absorbed across the intestinal mucosa while most other bRo5 compounds are not? Are such exceptional bRo5 compounds exclusively taken up by carrier-mediated transport or are they able to permeate the lipid bilayer (passive lipoidal diffusion)? Our experimental data with liposomes indicate that tetracycline, which violates one rule of the Ro5, and rifampicin, violating three of the rules, significantly permeate a phospholipid bilayer with kinetics similar to labetalol and metoprolol, respectively. Published data from experimental work and molecular dynamics simulations suggest that the formation of intramolecular H-bonds and the possibility to adopt an elongated shape besides the presence of a significant fraction of net neutral species facilitate lipid bilayer permeation. As an alternative to lipid bilayer permeation, carrier proteins can be targeted to improve absorption, with the potential drawbacks of drug-drug interactions and non-linear pharmacokinetics.
Assuntos
Absorção Intestinal , Bicamadas Lipídicas/metabolismo , Preparações Farmacêuticas/metabolismo , Animais , Humanos , Ligação de Hidrogênio , Mucosa Intestinal/metabolismo , Labetalol/metabolismo , Lipossomos , Metoprolol/metabolismo , Simulação de Dinâmica Molecular , Rifampina/metabolismo , Tetraciclina/metabolismoRESUMO
Tandem tracker: Here we introduce a method for studying the kinetics of protein-small-molecule interactions based on kinetic capillary electrophoresis (KCE) separation and MS detection. Due to the variety of KCE methods and MS modes available, the KCE-MS tandem is a highly versatile platform for label-free, solution-based kinetic studies of affinity interactions.
Assuntos
Eletroforese Capilar , Espectrometria de Massas , Proteínas/metabolismo , Bibliotecas de Moléculas Pequenas/metabolismo , Alprenolol/química , Alprenolol/metabolismo , Cinética , Labetalol/química , Labetalol/metabolismo , Orosomucoide/química , Orosomucoide/metabolismo , Pindolol/química , Pindolol/metabolismo , Propranolol/química , Propranolol/metabolismo , Ligação Proteica , Proteínas/química , Bibliotecas de Moléculas Pequenas/químicaRESUMO
PURPOSE: This study investigated the influence of gestational diabetes mellitus on the kinetic disposition and stereoselective metabolism of labetalol administered intravenously or orally. METHODS: Thirty hypertensive women during the last trimester of pregnancy were divided into four groups: non-diabetic and diabetic women treated with intravenous or oral labetalol. RESULTS: The pharmacokinetics of labetalol was not stereoselective in diabetic or non-diabetic pregnant women receiving the drug intravenously. However, oral administration of labetalol resulted in lower values of the area under the plasma concentration versus time curve (AUC) for the ß-blocker (RR) than for the other enantiomers in both diabetic and non-diabetic women. Gestational diabetes mellitus caused changes in the kinetic disposition of the labetalol stereoisomers when administered orally. The AUC values for the less potent adrenoceptor antagonist (SS) and for the α-blocking (SR) isomers were higher in diabetic than in non-diabetic pregnant women. CONCLUSIONS: The approximately 100% higher AUC values obtained for the (SR) isomer in diabetic pregnant women treated with oral labetalol may be of clinical relevance in terms of the α-blocking activity of this isomer.
Assuntos
Antagonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/farmacocinética , Diabetes Gestacional/metabolismo , Hipertensão Induzida pela Gravidez/metabolismo , Labetalol/metabolismo , Labetalol/farmacocinética , Administração Oral , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/sangue , Adulto , Área Sob a Curva , Pressão Sanguínea/efeitos dos fármacos , Feminino , Glucuronídeos/sangue , Glucuronídeos/metabolismo , Humanos , Hipertensão Induzida pela Gravidez/tratamento farmacológico , Hipertensão Induzida pela Gravidez/fisiopatologia , Injeções Intravenosas , Labetalol/administração & dosagem , Labetalol/sangue , Gravidez , Estereoisomerismo , Adulto JovemRESUMO
In this work, isothermal titration calorimetry (ITC) combined with zeta potential measurements was used to study the binding and partitioning of three beta-blockers, alprenolol, labetalol and propranolol, and the local anaesthetic tetracaine into liposomes. The thermodynamic parameters of enthalpy, entropy, the Gibbs energy and the binding constant were determined using the one site model. Furthermore, the binding constants corrected for the electrostatic contribution were used to assess the partition coefficients for the drugs. Also, the effect of the concentration, ionic strength, temperature and membrane curvature on the interaction was included in the evaluation.
Assuntos
Calorimetria/métodos , Lipossomos/química , Preparações Farmacêuticas/química , Termodinâmica , Algoritmos , Alprenolol/química , Alprenolol/metabolismo , Sítios de Ligação , Ligação Competitiva , Entropia , Cinética , Labetalol/química , Labetalol/metabolismo , Lipossomos/metabolismo , Modelos Químicos , Estrutura Molecular , Preparações Farmacêuticas/metabolismo , Fosfatidilcolinas/química , Fosfatidilgliceróis/química , Propranolol/química , Propranolol/metabolismo , Tetracaína/química , Tetracaína/metabolismoRESUMO
The authors recently reported the increased oral clearance of labetalol in pregnant women. To elucidate the mechanism of the elevated oral clearance, it was hypothesized that female hormones, at the high concentrations attainable during pregnancy, enhance hepatic metabolism of labetalol. Labetalol glucuronidation, which is the major elimination pathway of labetalol, was characterized by screening six recombinant human UGTs (UGT1A1, 1A4, 1A6, 1A9, 2B4, and 2B7) for their capacity to catalyse labetalol glucuronidation. The effect of female hormones (progesterone, oestradiol, oestriol, or oestrone) on the promoter activities of relevant UDP glucuronosyltransferases (UGT) was investigated using a luciferase reporter assay in HepG2 cells. The involvement of oestrogen receptor alpha (ERalpha) and pregnane X receptor (PXR) was examined by co-transfecting ERalpha- or PXR-constructs. UGT1A1 and UGT2B7 were identified as the major UGT enzymes producing labetalol glucuronides (trace amount of glucuronide conjugate was formed by UGT1A9). The activities of the UGT1A1 promoter containing PXR response elements were enhanced by progesterone, but not by oestrogens, indicating PXR-mediated induction of UGT1A1 promoter activity by progesterone. Results from semi-quantitative real-time polymerase chain reaction (PCR) assays are consistent with the above findings. This effect of progesterone on UGT1A1 promoter activities was concentration dependent. Promoter activities of UGT2B7 were not affected by either oestrogens or progesterone. The results suggest a potential role for progesterone in regulating labetalol elimination by modulating the expression of UGT1A1, leading to enhanced drug metabolism during pregnancy.
Assuntos
Anti-Hipertensivos/metabolismo , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Labetalol/metabolismo , Progesterona/farmacologia , Células Cultivadas , Relação Dose-Resposta a Droga , Humanos , Espectrometria de Massas , Regiões Promotoras Genéticas , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Transcrição GênicaRESUMO
We provide the first evidence that point mutations can constitutively activate the beta(1)-adrenergic receptor (AR). Leucine 322 of the beta(1)-AR in the C-terminal portion of its third intracellular loop was replaced with seven amino acids (I, T, E, F, C, A and K) differing in their physico-chemical properties. The beta(1)-AR mutants expressed in HEK-293 cells displayed various levels of constitutive activity which could be partially inhibited by some beta-blockers. The results of this study might have interesting implications for future studies aiming at elucidating the activation process of the beta(1)-AR as well as the mechanism of action of beta-blockers.
Assuntos
Agonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/metabolismo , Mutação Puntual , Receptores Adrenérgicos beta 1/genética , Receptores Adrenérgicos beta 1/metabolismo , Agonistas de Receptores Adrenérgicos beta 1 , Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Substituição de Aminoácidos , Betaxolol/metabolismo , Betaxolol/farmacologia , Carbazóis/metabolismo , Carbazóis/farmacologia , Carvedilol , Linhagem Celular/efeitos dos fármacos , Linhagem Celular/metabolismo , AMP Cíclico/metabolismo , Epinefrina/metabolismo , Epinefrina/farmacologia , Humanos , Imidazóis/metabolismo , Imidazóis/farmacologia , Isoproterenol/metabolismo , Isoproterenol/farmacologia , Labetalol/metabolismo , Labetalol/farmacologia , Practolol/metabolismo , Practolol/farmacologia , Propanolaminas/metabolismo , Propanolaminas/farmacologia , Receptores Adrenérgicos beta 2/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Timolol/metabolismo , Timolol/farmacologiaRESUMO
Stereoselective interaction of drugs with human serum transferrin in capillary zone electrophoresis is described. The substances passed a pseudo-stationary protein zone applied in a coated capillary and the possible chiral separation of the optical isomers was followed. Drugs with different structures were screened and the enantiomers of bupivacaine, propranolol and promethazine as well as the diastereomers of labetalol were resolved. Racemic mixtures of atenolol and pindolol enantiomers could not be resolved under these conditions.
Assuntos
Eletroforese Capilar/métodos , Preparações Farmacêuticas/metabolismo , Transferrina/metabolismo , Bupivacaína/química , Bupivacaína/metabolismo , Humanos , Concentração de Íons de Hidrogênio , Labetalol/química , Labetalol/metabolismo , Prometazina/química , Prometazina/metabolismo , Propranolol/química , Propranolol/metabolismo , EstereoisomerismoRESUMO
Dilevalol, the (R),(R)-isomer of labetalol, is a novel antihypertensive agent with both beta-adrenoreceptor activity and direct vasodilatory action. The biotransformation of dilevalol was studied in the rat, dog, monkey, and human. Nine metabolites were isolated and characterized by NMR spectroscopy and MS. The simple benzylic glucuronide is the major metabolite in the dog, monkey, and human, whereas the phenolic glucuronide is the major metabolite in the rat. Seven other metabolites that arise from phase 1 oxidation were also isolated, including a family of catechol-like metabolites formed by hydroxylation at the C3 position of the benzamide ring. This catechol also undergoes ring cyclization forming two novel indolic metabolites.
Assuntos
Labetalol/metabolismo , Animais , Biotransformação , Cães , Glucuronatos/urina , Humanos , Macaca fascicularis , Masculino , Ratos , Ratos Sprague-Dawley , Especificidade da EspécieRESUMO
Labetalol has been previously shown to cause significant maternal and fetal metabolic effects in pregnant sheep after maternal administration. To investigate these observations further, the present study describes the pharmacokinetics, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct fetal i.v. bolus (4 mg) administration. The fetal total body clearance of labetalol (50.45 +/- 1.37 ml m-1 kg-1), which was significantly higher than that previously determined in the ewe, was composed of transplacental and nonplacental CLs of 23.4 +/- 8.99 ml m-1 kg-1 and 27.05 +/- 10.36 ml m-1 kg-1, respectively. The maternal to fetal plasma labetalol area under the curve ratio was 0.031 +/- 0.002 and the CLmp and CLmn were 7.27 +/- 2.11 ml m-1 kg-1 and 30.5 +/- 5.94 ml m-1 kg-1, respectively. Labetalol concentrations in fetal tracheal fluid were consistently higher than that in fetal plasma. The glucuronide conjugate of labetalol was found in the amniotic fluid at up to 20 times the free drug concentration but the oxidative metabolite, 3-amino-1-phenyl-butane, was not detected in plasma or amniotic fluid samples. The fetal effect of labetalol was characterized by an acute lactic acidosis. The calculated hind limb arteriovenous lactate flux showed a net output of lactic acid equal to 3.85 +/- 2.05 g from the hind limb over 24 h after labetalol administration. Although the fetal exposure to labetalol in this study was roughly 4 times that after a 100-mg maternal bolus administration, the magnitude of fetal lactic acidosis was not significantly different in these studies. The clinical implications of the observations made in this study remain to be investigated.
Assuntos
Labetalol/metabolismo , Placenta/metabolismo , Animais , Gasometria , Feminino , Hemodinâmica/efeitos dos fármacos , Injeções Intravenosas , Labetalol/farmacocinética , Labetalol/farmacologia , Lactatos/sangue , Gravidez , OvinosRESUMO
A sensitive and selective assay has been developed for the identification and quantitation of 3-amino-1-phenyl butane (3-APB), a metabolite of labetalol, in biological fluids using electron impact gas chromatography/mass-selective detection. Samples were extracted with n-hexane, derivatized with heptafluorobutyric anhydride and chromatographed on a cross-linked fused-silica capillary column. A positive EI spectrum was obtained using a mass-selective detector. Identification of the metabolite was accomplished using an authentic standard; quantitation was performed in the selected ion monitoring mode using ions m/z 345 (M+) and 132. The assay was linear over the calibration range of 0.5-1000 ng of the analyte and the intra-sample coefficients of variation were less than 12% in all cases. The absolute recovery of 3-APB following extraction from urine and bile was found to be 102.9 +/- 4.9% and 98.3 +/- 1.45% (mean +/- SEM) respectively. The minimum quantitation limit of the assay was 0.5 ng ml-1 (approximately 2 pg injected). Application of the assay in a pharmacokinetic-pharmacodynamic study of labetalol in sheep is demonstrated. The metabolite was detected in urine and bile samples obtained from adult non-pregnant sheep following labetalol administration. The cumulative amount of 3-APB excreted in urine over 24 h was found to be 71.55 micrograms in one animal following a 100 mg dose of labetalol. Evidence for biliary excretion, glucuronidation and sulfation of 3-APB was also found.
Assuntos
Butilaminas/análise , Labetalol/metabolismo , Animais , Bile/química , Butilaminas/urina , Feminino , Cromatografia Gasosa-Espectrometria de Massas/métodos , Labetalol/farmacocinética , OvinosRESUMO
We previously identified 3-amino-1-phenylbutane (APB) as an oxidative N-dealkylated, metabolite of the antihypertensive agent labetalol. Labetalol has two asymmetric centers and is used clinically as a mixture of the four possible stereoisomers; APB has one asymmetric center. We now report an enantiospecific gas chromatographic/mass spectrometric assay for APB in urine. After adding the internal standard 1-methyl-2-phenoxyethylamine and alkalinizing, the urine samples were extracted with ether. The extracts were derivatized with the optically active acid chloride prepared from (S)-alpha-methoxy-alpha-trifluoromethylphenylacetic acid. The derivatives were separated by capillary gas chromatography and detected by electron capture negative ion chemical ionization mass spectrometry with selected ion monitoring. The derivative of the R enantiomer eluted first, and the [M--32]- ions were monitored for both the drug and the internal standard. The method was linear in the 0.05-2.5 micrograms enantiomer-1 ml-1 range and had inter-assay and intra-assay coefficients of variation of less than 6%. The assay was used in the analysis of urine samples from a patient in labetalol therapy and no interference was found. Further studies are needed to elucidate the oxidative metabolism of labetalol and its stereochemical aspects.
Assuntos
Butilaminas/urina , Labetalol/metabolismo , Adulto , Cromatografia Gasosa-Espectrometria de Massas/métodos , Humanos , MasculinoRESUMO
Glucuronidation is known to be a major metabolic pathway for labetalol. As the drug contains a phenolic and an alcoholic hydroxy group, in principle two regio isomeric glucuronides can be formed. By incubating the substrate labetalol with bovine liver microsomes, in the presence of the co-substrate UDP-glucuronic acid, both hydroxy positions were glucuronidated. The different glucuronides were isolated from the incubation mixture using Bond-Elut extraction cartridges and separated by means of high performance liquid chromatography. The formation of glucuronides was confirmed by performing reference incubations using radiolabeled UDP-glucuronic acid. Structure elucidation of the various glucuronides was done by nuclear magnetic resonance, ultraviolet spectroscopy, and mass spectrometry.
Assuntos
Labetalol/metabolismo , Microssomos Hepáticos/metabolismo , Animais , Bovinos , Cromatografia Líquida de Alta Pressão , Glucuronatos/isolamento & purificação , Glucuronatos/metabolismo , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Espectrofotometria Ultravioleta , Uridina Difosfato Ácido Glucurônico/metabolismoRESUMO
Previous studies on the metabolic fate of antihypertensive agent labetalol in humans identified only conjugated metabolites of the drug and accounted for only a portion of the dose. In this study, urine samples obtained from three patients on chronic labetalol therapy for hypertension were analyzed initially by thin layer chromatography for the presence of other metabolites. All three urine samples were found to contain 3-amino-1-phenylbutane. The identify of this metabolite in one of the urine samples was confirmed by electron capture negative-ion chemical ionization mass spectrometry. The mass spectrometry experiments also identified the presence in the urine sample of the D-hydroxy derivative of 3-amino-1-phenylbutane. The two metabolites are the result of oxidative biotransformations of labetalol. 3-Amino-1-phenylbutane has been reported to be a potent sympathomimetic agent, and the question arises whether the newly identified metabolites of labetalol contribute to its pharmacological effects.
Assuntos
Hipertensão/metabolismo , Labetalol/metabolismo , Adulto , Biotransformação , Butilaminas/urina , Cromatografia em Camada Fina , Feminino , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/urina , Labetalol/uso terapêutico , Labetalol/urina , Masculino , Pessoa de Meia-Idade , OxirreduçãoRESUMO
This is an assay for labetalol in plasma by "high-performance" liquid chromatography, with 5-(2-[4-(4-chlorophenyl)ethyl]) salicylamide hemihydrate as the internal standard. Plasma samples (500 microL) are extracted with acetonitrile, evaporated under nitrogen, reconstituted in the mobile phase, and injected onto a PRP-1 (Hamilton) column packed with particles of poly(styrene-divinylbenzene) copolymer. Fluorescence, enhanced by post-column introduction of NH4OH, was measured in the effluent (excitation wavelength 340 nm, emission wavelength 418 nm). Retention times for labetalol and the internal standard were 1.99 and 3.32 min, respectively. Inter- and intraday CVs for high and low concentrations of the drug were less than 7.5%. The assay standard curve is linear from 1 to 250 micrograms/L. Some commonly co-administered drugs were tested and did not interfere.
Assuntos
Labetalol/sangue , Cromatografia Líquida de Alta Pressão , Humanos , Falência Renal Crônica/metabolismo , Cinética , Labetalol/metabolismo , Manejo de EspécimesRESUMO
A case of intravenous labetalol in the treatment of a resistant hypertensive emergency is reported. Although there have been several reports of the use of oral labetalol in resistant hypertension, no intravenous administration in hypertensive emergency resistant to other drugs has been reported to date. A 36-year-old black female with BP of 270/160 mm Hg with complaints greater than one month's duration of dizziness, severe headaches, blurred vision, shortness of breath, vomiting, palpitations, flushing, agitation, diarrhea, weakness, and weight loss, was treated successfully with intravenous labetalol after she failed to respond to other established parenteral antihypertensive drugs. The patient received labetalol 20 mg iv bolus, and then 20 mg every ten minutes until a cumulative dose of 200 mg was attained. Labetalol produced a prompt but smooth reduction in BP without any reflex tachycardia or other adverse effects. Intravenous labetalol may be safe and effective for the management of rapid BP control in hypertensive emergencies resistant to other parenteral antihypertensive agents.